Form 4: Collegium Pharmaceutical EVP Scott Dreyer Sells Shares Under 10b5-1 Plan

Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold shares of common stock on March 6th and 7th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Scott Dreyer, the EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold shares of the company's common stock on March 6th and 7th, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• On March 6, 2025, 3,295 shares were sold at a weighted average price of $30.0011, with individual prices ranging from $30.00 to $30.02.
• On March 7, 2025, 2,348 shares were sold at a weighted average price of $30.0025, with individual prices ranging from $30.00 to $30.01.
• Following these transactions, Dreyer directly owns 142,063 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of insider stock sales under a pre-arranged plan, indicating a neutral sentiment. It doesn't inherently suggest positive or negative implications for the company's performance.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Comparison to Industry Standards

• It's common for executives at publicly traded pharmaceutical companies to utilize 10b5-1 trading plans to diversify their holdings or manage personal finances.
• Comparing Dreyer's transactions to those of executives at similar-sized pharmaceutical companies like Pacira BioSciences or Heron Therapeutics would provide context on the scale and frequency of such sales.
• The weighted average prices of approximately $30.00 per share can be benchmarked against the average trading volume and price volatility of Collegium Pharmaceutical's stock in the days leading up to and following the transactions.

Stakeholder Impact

• The stock sales could have a minor, temporary impact on the stock price, but the existence of a 10b5-1 plan mitigates concerns about insider information being used.
• Employees and other stakeholders are unlikely to be directly affected by these transactions.

Key Dates